Skip to Content

Pitressin (vasopressin) Disease Interactions

There are 4 disease interactions with Pitressin (vasopressin):


Vasopressin (applies to Pitressin) nephritis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glomerulonephritis

Chronic nephritis with nitrogen retention contraindicates the use of vasopressin until reasonable nitrogen blood levels have been attained.


Vasopressin (applies to Pitressin) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Vasopressin is contraindicated in patients with chronic nephritis with nitrogen retention. This until reasonable nitrogen blood levels have been attained.


Vasopressin (applies to Pitressin) vascular disease

Major Potential Hazard, High plausibility. Applicable conditions: Cerebral Vascular Disorder, Peripheral Arterial Disease, Ischemic Heart Disease

Vasopressin should not be used in patients with vascular disease, especially disease of the coronary arteries, except with extreme caution. In such patients, even small doses may precipitate anginal pain, and large doses may cause myocardial infarction. If a decision is made to use the drug, ECG monitoring should be performed periodically during therapy.


  1. Khokhar AM, Slater JD, Ma J, Ramage CM "The cardiovascular effect of vasopressin in relation to its plasma concentration in man and its relevance to high blood pressure." Clin Endocrinol (Oxf) 13 (1980): 259-66
  2. Beller BM, Trevino A, Urban E "Pitressin-induced myocardial injury and depression in a young woman." Am J Med 51 (1971): 675-9
  3. Brearley S, Hawker PC, Dykes PW, Keighley MR "A lethal complication of peripheral vein vasopressin infusion." Hepatogastroenterology 32 (1985): 224-5
  4. Kelly KJ, Stang JM, Mekhjian HS "Vasopressin provocation of ventricular dysrhythmia." Ann Intern Med 92 (1980): 205-6
  5. "Product Information. Pitressin (vasopressin)." Parke-Davis, Morris Plains, NJ.
  6. Colombani P "Upper extremity gangrene secondary to superior mesenteric artery infusion of vasopressin." Dig Dis Sci 27 (1982): 367-9
  7. Jacoby AG, Wiegman MV "Cardiovascular complications of intravenous vasopressin therapy." Focus Crit Care 17 (1990): 63-6
  8. Greenwald RA, Rheingold OJ, Chiprut RO, Rogers AI "Local gangrene: a complication of peripheral Pitressin therapy for bleeding esophageal varices." Gastroenterology 74 (1978): 744-6
  9. Wormser GP, Kornblee LV, Gottfried EB "Cutaneous necrosis following peripheral intravenous vasopressin therapy." Cutis 29 (1982): 249-52
  10. Lambert M, de Peyer R, Muller AF "Reversible ischemic colitis after intravenous vasopressin therapy." JAMA 247 (1982): 666-7
  11. Butow KW, de Witt TW, Jacobs FJ "Ornithine-vasopressin gangrene and reconstruction of the upper lip. Case report." J Craniomaxillofac Surg 17 (1989): 88-91
View all 11 references

Vasopressin/desmopressin (applies to Pitressin) fluid overload/hyponatremia

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Seizures, Asthma, Fluid Retention, Migraine

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.


  1. "Product Information. Pitressin (vasopressin)." Parke-Davis, Morris Plains, NJ.
  2. Robson WLM, Norgaard JP, Leung AKC "Hyponatremia in patients with nocturnal enuresis treated with DDAVP." Eur J Pediatr 155 (1996): 959-62
  3. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO.
  4. "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.
  5. Tulandi T, Beique F, Kimia M "Pulmonary edema: a complication of local injection of vasopressin at laparoscopy." Fertil Steril 66 (1996): 478-80
  6. Williford SL "Water intoxication in patients treated with desmopressin - reply." Pharmacotherapy 16 (1996): 970
  7. Lin TW, Kuo YS "Acute pulmonary oedema following administration of vasopressin for control of massive GI tract haemorrhage in a major burn patient." Burns 22 (1996): 73-5
  8. Robson WLM "Water intoxication in patients treated with desmopressin." Pharmacotherapy 16 (1996): 969-70
View all 8 references

Pitressin (vasopressin) drug interactions

There are 274 drug interactions with Pitressin (vasopressin)

Pitressin (vasopressin) alcohol/food interactions

There is 1 alcohol/food interaction with Pitressin (vasopressin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.